Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Amarin Corporation PLC Enters Into An Underwriting Agreement With Citigroup Global Markets Inc. And Jefferies LLC, Relating To Issuance And Sale-Form 8-K


Thursday, 11 Jul 2013 05:45am EDT 

Amarin Corporation PLC reported in it's Form 8-K that on July 8, 2013, the Company, entered into an Underwriting Agreement with Citigroup Global Markets Inc. and Jefferies LLC (the Underwriters), relating to the issuance and sale of up to 24,955,000 American Depositary Shares (ADSs), including 3,255,000 ADSs issuable to the Underwriters pursuant to a 30-day option, with each ADS representing one of the Company’s ordinary shares, par value GBP0.50 per share. The Underwriters purchased the ADSs from the Company at a price of $5.60 per ADS. The net proceeds to US from the Offering are expected to be approximately $121.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses, assuming no exercise of the option by the Underwriters. The Offering is expected to close on or about July 12, 2013, subject to customary closing conditions. The Company currently intends to use the net proceeds from the Offering to continue the commercial launch of Vascepa capsules in the MARINE indication, prepare for and commercially launch Vascepa in the ANCHOR indication, if approved, advance the Company’s REDUCE-IT cardiovascular outcomes trial, and for general corporate and working capital purposes. 

Company Quote

1.52
0.01 +0.66%
21 Jul 2014